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Gregory Y. H. Lip3,4
It is unclear whether the two once-daily dosing non-vitamin K antagonist oral anticoagulants (NoACs), 
edoxaban and rivaroxaban, have similar effectiveness and safety in Asian patients with non-valvular 
atrial fibrillation (AF). This study aimed to compare the effectiveness and safety of edoxaban and 
rivaroxaban in a Korean population with non-valvular AF. Using the Korean National Health Insurance 
Service database from January 2014 to December 2016, we compared the risk of ischemic stroke, 
intracranial hemorrhage (ICH), hospitalization for gastrointestinal (GI) bleeding, hospitalization for 
major bleeding, all-cause death, and composite outcome in a 3:1 propensity score matched cohort in 
patients with AF who were naïve to rivaroxaban (n = 12,369) and edoxaban (n = 4,123). Hazard ratios for 
the six clinical outcomes were analyzed using Cox regression analysis with rivaroxaban as the reference. 
Baseline characteristics were balanced between the two groups (median age, 71 years; median 
CHA2Ds2-VASc score, 3; 56% of patients received a reduced dose). Edoxaban users showed comparable 
results in all six clinical outcomes (all p = nonsignificant) when compared to rivaroxaban users for total, 
standard, and reduced doses. We provide for the first time the comparison of effectiveness and safety 
between the two once-daily NoACs in a large-scale Asian AF population. In both standard and reduced 
dose regimens, edoxaban showed comparable effectiveness and safety compared to rivaroxaban.
For decades, vitamin K antagonists (VKAs) were the only available oral anticoagulants (OACs) for stroke preven-
tion in patients with atrial fibrillation (AF)1. Although VKAs are highly effective for the prevention of stroke, their 
use in patients with AF has been limited by the inconvenience resulting from a narrow therapeutic range and the 
need for frequent monitoring2,3. Furthermore, Asian patients on VKAs are more prone to bleeding, particularly 
to intracranial hemorrhage (ICH), than non-Asian patients4,5.
The recent introduction of non-vitamin K antagonist oral anticoagulants (NOACs) provides effective, safe, 
and convenient alternatives to VKAs in patients with non-valvular AF6. In subgroup analyses of pivotal rand-
omized clinical trials (RCTs), Asians showed greater benefits from NOACs than non-Asians reducing the risk 
of stroke and ICH, but it is still controversial for risk of gastrointestinal (GI) bleeding5,7. In recent observational 
data from Asians, rivaroxaban showed comparable efficacy results, but increased the risk of hospitalization for 
GI bleeding compared to warfarin, while edoxaban was associated with a significant lower risk of hospitalization 
for GI bleeding than warfarin8,9. Among four available NOACs, rivaroxaban and edoxaban have the advantage 
of once-daily administration, allowing convenience and lower pill burden, especially in patients desiring a single 
dose regimen, thus prescription of these two NOACs has markedly increased10. A head-to-head comparison 
of two treatment could provide useful guidance for physician to choose the most appropriate NOAC for their 
patients. Therefore, we sought to compare the effectiveness and safety of two once-daily NOACs in the Korean 
patients with non-valvular AF.
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Methods
The data from the Korean National Health Insurance Service (NHIS) were analyzed. Each patient’s demographic 
information, International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) diag-
nosis codes, procedure codes, and prescription dispending records in inpatient and outpatient services were 
collected and analyzed. NHIS is a single insurer covering the entire Korean population (approximately 50 million 
people). Among the enrollees who had a periodic health check-up at least every 2 years, several basic laboratory 
tests and anthropometric measurements could be obtained. This study was exempted from review by the Seoul 
National University Hospital Institutional Review Board (E-1802-010-918).
Study design and cohort definition. Patients who were diagnosed with AF (ICD-10-CM codes I480–
I484, I489) between January 2013 and December 2016 were identified. Patients with the following conditions 
were excluded: (1) mitral stenosis or preexisting mechanical heart valves; (2) previous OAC prescription between 
January 2013 and December 2013 to analyze only those who were new rivaroxaban and edoxaban users; (3) 
a potential alternative indication for OAC treatment, such as deep vein thrombosis, pulmonary embolism, or 
joint replacement; (4) end-stage renal disease; and (5) history of ischemic stroke, ICH, and GI bleeding events. 
In patients with diagnostic coding of ischemic stroke, ICH, or GI bleeding in the NHIS claims database, incident 
episodes of those events were not validated to differentiate them from previous episodes9,11. The patient enroll-
ment flow is summarized in Fig. 1.
Baseline covariates. Patients’ baseline characteristics, including age, sex, and comorbidities [hypertension, 
diabetes mellitus, dyslipidemia, congestive heart failure, peripheral artery disease (PAD), chronic obstructive 
pulmonary disease (COPD), and prior history of myocardial infarction (MI)], were obtained. Patients’ comor-
bidities were defined by the ICD-10-CM codes with hospitalization and prescription records within the 1-year 
period prior to the index date (Supplementary Table 1) and coded as binary variables. CHA2DS2-VASc score was 
calculated as a measure of stroke risk in patients with AF by assigning 1 point each for age between 65 and 74 
years, female sex, and the presence of hypertension, diabetes mellitus, congestive heart failure, and vascular dis-
ease (PAD or prior MI) and adding 2 points each for age of 75 years or older and prior stroke/transient ischemic 
attack/systemic thromboembolism12. The CHADS2 score that was used in ROCKET-AF and ENGAGE-AF tri-
als13,14, was also calculated as follows: 2 points were assigned for prior stroke/transient ischemic attack and 1 point 
each was assigned for age ≥75 years, hypertension, diabetes mellitus, or recent congestive heart failure15.
Clinical outcomes and follow-up. The date of the first rivaroxaban or edoxaban prescription during the 
study period was defined as the index date. To determine the effectiveness and safety of rivaroxaban and edox-
aban, six clinical outcomes were identified during study period (between January 2014 and December 2016) as 
follow: ischemic stroke, ICH, hospitalization for GI bleeding, hospitalization for major bleeding, all-cause death, 
and composite outcome of ischemic stroke + ICH + all-cause death9,11. Clinical outcomes were defined by the 
ICD-10-CM codes, and detailed definitions are described in Supplementary Table 1. To assess the outcomes, 
patients were censored at the occurrence of outcome events, or the end of the study period, whichever came first. 
To balance the follow-up period between two groups, patients were censored at 1 year after index data9,16.
statistical methods. For the comparison between rivaroxaban and edoxaban-treated groups, a propensity 
score matching analysis was performed17,18. The propensity of being in the rivaroxaban or edoxaban group was 
Figure 1. Study population enrollment flow. Abbreviation: AF, atrial fibrillation; ESRD, end-stage renal disease; 
GI, gastrointestinal; ICH, intracranial hemorrhage; OAC, oral anticoagulants.
3Scientific RepoRts |          (2019) 9:6690  | https://doi.org/10.1038/s41598-019-43224-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
estimated with a logistic regression model with all covariates in the baseline characteristics as follows: age, sex, 
CHA2DS2-VASc score, hypertension, diabetes mellitus, dyslipidemia, congestive heart failure, prior MI, PAD, and 
COPD (Supplementary Table 2).
In both rivaroxaban and edoxaban groups, predefined dose reduction criteria were used, because the baseline 
characteristics of patients taking reduced dose of NOACs (rivaroxaban 15/10 mg and edoxaban 30 mg) might be 
different from those of patients taking a standard dose of NOACs (rivaroxaban 20 mg and edoxaban 60 mg)13,14. 
For separate analysis by dose regimens, both standard (rivaroxaban 20 mg and edoxaban 60 mg) and reduced 
dose (rivaroxaban 15/10 mg and edoxaban 30 mg) groups were matched separately based on propensity scores.
Each patient in edoxaban group was matched to three patients in the rivaroxaban group (1:3 matching) 
because there were more patients who received rivaroxaban than edoxaban (Fig. 1). The greedy, nearest-neighbor 
method without replacement with a caliper of 0.01 of the propensity scores was used for matching17. Baseline 
characteristics were presented descriptively before and after propensity score matching. Absolute standardized 
difference (ASD) was used to assess the balance of covariates after matching. An ASD of ≤0.1 (10%) indicated an 
acceptable difference between the two treatment groups by each covariate19.
Crude incidence rates of six clinical outcomes are presented as number of events per 100 person-years (100 
PY). The risk of clinical outcomes over time for edoxaban as compared to rivaroxaban (reference) was analyzed 
suing a survival analysis, with the Kaplan–Meier method and log-rank test for univariate analysis and Cox pro-
portional hazards regression model. Because all baseline covariates were balanced after propensity score match-
ing, the Cox proportional hazards regression included only treatment as the independent variable. Statistical 
significance was defined as a p value < 0.05. All statistical analyses were performed using SAS version 9.3 software 
(SAS Institute Inc., Cary, NC, USA).
subgroup and sensitivity analyses. Subgroup analyses were performed based on patients’ age, sex, esti-
mated stroke risk, and renal function. Age subgroups were categorized as follows: <65 years, 65–74 years, and ≥75 
years. For the estimated stroke risk subgroups, patients were categorized into two groups using CHA2DS2-VASc 
scores: 0–2 and ≥3. For the renal function subgroups, patients were categorized into two subgroups by creatinine 
clearance (CrCl): ≤50 mL/min and >50 mL/min. Subgroup analysis was also performed by patients’ body weight 
(≤60 kg and >60 kg). Furthermore, patients with CrCl >95 mL/min were analyzed separately to assess the effec-
tiveness and safety of rivaroxaban and edoxaban in patients with “high normal” renal function20.
In each subgroup, the balance of baseline characteristics between rivaroxaban and edoxaban groups was eval-
uated and the covariates with ASD >0.1 (10%) were included in the Cox proportional hazards model. In each 
subgroup analysis, the interaction between the two treatment modalities in the specific subgroups was evaluated 
and the statistical significance of the interaction was defined as a p value for interaction <0.1.
A sensitivity analysis was conducted with restriction of the follow-up duration to 6 months because of the 
shorter follow-up duration of the edoxaban group. Furthermore, we also performed a sensitivity analysis among 
patients who were only enrolled after February 2016, when edoxaban was introduced into the market9.
Results
During a median of 0.8 years of follow-up [interquartile range (IQR) 0.3–0.9 years)], a total of 27,149 patients 
with AF newly initiated rivaroxaban (n = 22,949) and edoxaban (n = 4,200). Before propensity score matching, 
rivaroxaban users had significantly higher CHADS2 and CHA2DS2-VASc scores, and a higher likelihood of hyper-
tension and heart failure compared to edoxaban users (Table 1). Before matching, 51.2% of rivaroxaban users and 
56.8% of edoxaban users were prescribed reduced dose regimens. Because of different indications for the standard 
and reduced doses, the baseline characteristics between the two groups were significantly different in each NOAC 
group (Supplementary Table 3). Patients taking a reduced NOAC dose were significantly older, more likely to 
be female, and had higher CHA2DS2-VASc and CHADS2 scores in each NOAC group (Supplementary Table 3).
Characteristics of study population in the propensity score-matched cohort. After 3:1 propen-
sity score matching, 12,369 rivaroxaban-treated patients were successfully matched to 4,123 edoxaban-treated 
patients (Fig. 1). The mean age was 71 ± 10 years (median 72 years, IQR 65–78 years) and mean CHA2DS2-VASc 
score was 3.3 ± 1.6 (median 3, IQR 2–4). In matched cohorts, 56% of patients received a reduced NOAC dose 
(rivaroxaban 15/10 mg and edoxaban 30 mg). Overall, the two matched cohorts were well balanced across all 
covariates (Table 1, Supplementary Table 4 and Fig. 1). The median follow-up duration was 0.8 years (IQR 0.4–0.9 
years) in the rivaroxaban cohort and 0.3 years (IQR 0.1–0.5 years) in the edoxaban cohort (p < 0.001).
Ischemic stroke, intracranial hemorrhage, hospitalization for gastrointestinal bleeding, hos-
pitalization for major bleeding, all-cause death and composite outcome. Hazard ratios (HRs) of 
edoxaban treatment with rivaroxaban as the reference were presented in Fig. 2. No significant differences were 
found between edoxaban and rivaroxaban for all six clinical outcomes (Fig. 2). For hospitalization for GI bleed-
ing, a trend favoring edoxaban compared to rivaroxaban was detected without statistical significance (HR 0.775, 
95% CI 0.515–1.124, p = 0.197). Detailed data for the number of events and crude incidence rates according to 
treatment are summarized in Table 2. The cumulative incidence curves for six clinical outcomes are shown in 
Fig. 3.
sensitivity analyses. In sensitivity analyses for adjusting the differences in follow-up duration to 6 months, 
HR trends for all clinical outcomes were similar to the main results (Fig. 4). While comparing those with same 
period of enrollment, edoxaban showed lower risks of hospitalization for GI bleeding (HR 0.698, 95% CI 0.546–
0.880, p = 0.002), hospitalization for major bleeding (HR 0.628, 95% CI 0.384–0.977, p = 0.038), all-cause death 
(HR 0.663, 95% CI 0.443–0.957, p = 0.027), and composite outcomes (HR 0.766, 95% CI 0.628–0.927, p = 0.005) 
compared to rivaroxaban (Fig. 4).
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outcomes according to dose regimens. The cumulative incidences of six clinical outcomes are shown in 
Supplementary Figs 2 and 3. Compared to the standard dose rivaroxaban group, patients receiving the standard 
dose edoxaban had similar risks of ischemic stroke and ICH (HR 0.819, 95% CI 0.239–2.148, p = 0.714) (Fig. 2). 
Among patients taking the reduced dose regimen, both rivaroxaban and edoxaban showed similar risks for all six 
clinical outcomes (Fig. 2). HRs of edoxaban compared to rivaroxaban were generally consistent in both standard 
and reduced dose regimens. No significant interaction was found between treatment and dose regimens in all six 
clinical outcomes (Figs 5 and 6). Detailed data for the number of events and crude incidence rates according to 
treatment by dose regimens are summarized in Table 2.
subgroup analysis. HRs were generally consistent among subgroups (Figs 5 and 6 and Supplementary 
Table 5). Ischemic stroke, ICH, hospitalization for GI bleeding, hospitalization for major bleeding, all-cause 
death, and composite outcome were all consistent across the three age subgroups, for rivaroxaban and edox-
aban, with no significant interaction detected. No significant interaction was found between treatment and sex in 
regard to all six clinical outcomes.
Across the lower and higher stroke risks groups (CHA2DS2-VASc score 0–2 and ≥3), no significant difference 
was found between rivaroxaban and edoxaban in six clinical outcomes.
Among patients with available CrCl value (80% of population in each treatment group), 654 (5%) patients 
had moderate renal dysfunction (CrCl ≤50 mL/min). Edoxaban and rivaroxaban showed generally comparable 
outcomes in both groups stratified by renal function (Figs 5 and 6). Although there was no significant interaction 
between treatment and renal function, edoxaban was associated with lower risk of hospitalization for GI bleeding 
compared to rivaroxaban in patients with CrCl >50 mL/min (HR 0.455, 95% CI 0.202–0.887, p = 0.034). The 
incidence of ischemic stroke was also not significantly different between the edoxaban and rivaroxaban users 
(2.21 vs. 2.41 per 100 PY) in patients with “high normal” renal function (CrCl >95 mL/min). In patients with 
“high normal” renal function, edoxaban use did not increase the risk of ischemic stroke compared to rivaroxaban 
use (HR, 0.706; 95% CI 0.205–1.858; p = 0.524).
Edoxaban and rivaroxaban showed generally comparable outcomes in both groups stratified by body weight, 
except for composite outcome (Figs 5 and 6). Edoxaban showed better composite outcome than rivaroxaban in 
patients with body weight >60 kg, of borderline significance (HR 0.672, 95% CI 0.434–0.998, p = 0.049, p for 
interaction = 0.058).
Before propensity score matching After propensity score matching
Rivaroxaban 
(n = 22,949)
Edoxaban 
(n = 4,200) ASD
Rivaroxaban 
(n = 12,369)
Edoxaban 
(n = 4,123) ASD
Age, years
  Mean ± SD 71.5 ± 10.0 70.8 ± 10.0 0.067 71.1 ± 10.0 70.8 ± 10.0 0.037
  Median (IQR) 73 (66–78) 72 (65–78) 72 (65–78) 72 (65–78)
  <65 4,899 (21.4) 992 (23.6) 2,850 (23.0) 977 (23.7)
  65–74 8,584 (37.4) 1,606 (38.2) 4,622 (37.4) 1,570 (38.1)
  ≥75 9,466 (41.3) 1,602 (38.1) 4,641 (38.1) 1,467 (36.1)
Men 12,271 (53.5) 2,271 (54.1) 0.473 6,770 (54.7) 2,270 (55.1) 0.006
CHA2DS2-VASc score
  Mean ± SD 3.62 ± 1.68 3.24 ± 1.62 0.231 3.27 ± 1.61 3.26 ± 1.63 0.006
  Median (IQR) 4 (2–5) 3 (2–4) 3 (2–4) 3 (2–4)
  0–1 2,103 (9.2) 561 (13.4) 1,601 (12.9) 549 (13.3)
  2–3 9,171 (40.0) 1,885 (44.9) 5,468 (44.2) 1,826 (44.3)
  ≥4 11,675 (50.9) 1,754 (41.8) 5,300 (42.9) 1,748 (42.4)
CHADS2 score
  Mean ± SD 1.93 ± 1.22 1.63 ± 1.16 0.247 1.69 ± 1.15 1.65 ± 1.16 0.034
  Median (IQR) 2 (1–3) 2 (1–2) 2 (1–2) 2 (1–2)
  Hypertension 16,740 (72.9) 2,824 (67.2) 0.125 8,632 (69.8) 2,824 (68.5) 0.028
  Diabetes mellitus 5,415 (23.6) 845 (20.1) 0.084 2,477 (20.0) 845 (20.5) 0.012
  Dyslipidemia 9,611 (41.9) 1,660 (39.5) 0.048 4,679 (37.8) 1,654 (40.1) 0.047
  Heart failure 7,320 (31.9) 948 (22.6) 0.211 2,846 (23.0) 948 (23.0) 0.004
  Prior MI 775 (3.4) 97 (2.3) 0.064 251 (2.0) 97 (2.4) 0.022
  PAD 4,109 (17.9) 710 (16.9) 0.026 1,940 (15.7) 697 (16.9) 0.033
  COPD 4,618 (20.1) 748 (17.8) 0.059 2,012 (16.3) 738 (17.9) 0.043
Table 1. Baseline characteristics before and after propensity score matching by treatment group. Categorical 
variables, n (%). Abbreviation: ASD, absolute standardized difference; COPD, chronic obstructive pulmonary 
disease; IQR, interquartile range; MI, myocardial infarction; PAD, peripheral artery disease; SD, standard 
deviation.
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Discussion
To our knowledge, this is the first head-to-head comparison of the effectiveness and safety of the two once-daily 
NOACs (rivaroxaban and edoxaban) in a large-scale Asian population with non-valvular AF. We demonstrated 
that rivaroxaban and edoxaban use was associated with similar risks of ischemic stroke, ICH, all-cause death and 
the composite outcome.
Our data showed that both once-daily NOAC regimens were associated with similarly well results in 
“real-world” clinical practice. Both showed similar efficacy and safety compared to warfarin in large randomized 
clinical trials (RCTs)13,14. In the ROCKET-AF trial13, rivaroxaban (n = 7,131) was non-inferior to warfarin for 
stroke/systemic embolism prevention and showed a similar risk of major and clinically relevant non-major bleed-
ing. Although rivaroxaban was associated with a lower risk of ICH (0.5% vs. 0.7%, p = 0.02), major GI bleed-
ing was more frequent in the rivaroxaban group than in the warfarin group (3.2% vs. 2.2%, p < 0.001). In the 
ENGAGE-AF trial14, high dose edoxaban regimen (HDER, 60/30 mg arm, n = 7,035) was noninferior for stroke/
systemic embolism compared to warfarin, but showed a reduced risk of major bleeding, mainly driven by a reduc-
tion in ICH. Edoxaban significantly reduced ICH by 53%, but increased major GI bleeding by 23% compared to 
warfarin.
Despite the reassuring data from these pivotal RCTs evaluating the efficacy and safety of rivaroxaban and 
edoxaban compared to warfarin, further investigation is needed given that the baseline characteristics of two 
Figure 2. Hazard ratios of six clinical outcomes in rivaroxaban versus edoxaban groups. Abbreviation: CI, 
confidence interval; GI, gastrointestinal; HR, hazard ratio; ICH, intracranial hemorrhage.
Total R versus E Standard dose Reduced dose
Number of events (IR*) Number of events (IR*) Number of events (IR*)
R
(n = 12,369)
E
(n = 4,123)
R 20 mg
(n = 5,445)
E 60 mg
(n = 1,815)
R 15/10 mg
(n = 6,924)
E 30 mg
(n = 2,308)
Ischemic stroke 226 (2.76) 38 (3.10) 74 (1.96) 13 (2.34) 152 (3.45) 25 (3.74)
ICH 80 (0.97) 10 (0.81) 31 (0.82) 4 (0.72) 49 (1.10) 6 (0.89)
Hospitalization for GI bleeding 152 (1.85) 20 (1.63) 54 (1.43) 5 (0.90) 98 (2.21) 15 (2.24)
Hospitalization for major bleeding 228 (2.79) 30 (2.45) 84 (2.23) 9 (1.62) 144 (3.26) 21 (3.14)
All-cause death 490 (5.93) 75 (6.09) 136 (3.58) 18 (3.23) 354 (7.93) 57 (8.47)
Ischemic stroke + ICH + all-cause death 722 (8.86) 115 (9.41) 225 (5.99) 32 (5.77) 497 (11.30) 83 (12.43)
Table 2. Number of patients with event and crude incidence rates of six study outcomes. *IR, per 100 
person-years. Abbreviation: CI, confidence interval; E, edoxaban; GI, gastrointestinal; HR, hazard ratio; ICH, 
intracranial hemorrhage; IR, incidence rate; R, rivaroxaban.
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studies were different. Patients enrolled in the ROCKET-AF tended to have higher CHADS2 scores than those 
included in the ENGAGE-AF trial (mean CHADS2 score, 3.5 vs. 2.8, respectively)13,14. In addition, the perfor-
mance of warfarin group reflected by time in therapeutic range (TTR) was different between ROCKET-AF (55%) 
and ENGAGE-AF (68%). These trial population differences might make the indirect comparison between rivar-
oxaban and edoxaban by extrapolating from two pivotal clinical trials difficult. Furthermore, these RCTs included 
a relatively small proportion of Asians (6.5% in ROCKET-AF and 9.2% in ENGAGE-AF), as well as a smaller 
proportion of patients who received the reduced dose regimen (21% in ROCKET-AF and 25.4% in ENGAGE-AF) 
when compared with Asian “real-world” clinical settings8,11.
Several studies have reported the results of indirect and direct comparisons among three NOACs, including 
rivaroxaban, dabigatran, and apixaban, based on “real-world” observational databases8,11,21–23. Given the results 
of indirect comparisons using warfarin as a common comparator, the risk of major bleeding with rivaroxaban did 
not significantly differ from that with warfarin, but resulted in more GI bleeding21,22. The results of comparisons 
with dabigatran or apixaban found that rivaroxaban was associated with a higher risk of major bleeding and GI 
bleeding22,23. When focused on the Asian population, compared to warfarin, rivaroxaban was associated with 
reduced risks of ischemic stroke, ICH, and all-cause death without significantly increasing the risk for hospitali-
zation for GI bleeding (HR, 1.43; 95% CI, 0.88–2.33) and major bleeding (HR, 0.77; 95% CI, 0.53–1.13)8.
In general, data from observational cohorts has provided complementary and consistent evidence on the effi-
cacy and safety of the NOACs to those obtained in pivotal RCTs24. Recently, we reported a comparison between 
edoxaban and warfarin in a large nationwide Asian cohort and found that edoxaban was associated with a lower 
risk of ischemic stroke, ICH, and all-cause death9. Furthermore, edoxaban significantly reduced the risk of hospi-
talization for GI bleeding and major bleeding in Asian population.
Our results were inconsistent with main results of ENGAGE-AF, but we should consider the significant inter-
action between non-Asian and Asian in bleeding outcomes7 and the minority of Asians included in the RCTs. 
Of note, in the pooled meta-analysis of 4 pivotal RCTs, the increase risk of GI bleeding was only significant in 
non-Asian patients and a significant interaction was found between non-Asian and Asian patients6.
Given that some patients (and physicians) express a preference for the convenience of once-daily dosing, a 
recurrent question is whether rivaroxaban is better or comparable to edoxaban in terms of efficacy and safety. In 
the absence of head-to-head trials, Skjøth et al. performed an indirect comparison analysis using the data from 
the 4 pivotal RCTs and found that rivaroxaban use was associated with significantly more major and/or clinically 
relevant non-major bleeding and a nonsignificant increase in hospitalization for GI bleeding compared to edox-
aban25. In line with previous study, we found that the two once-daily dosing NOACs showed overall comparable 
outcomes, whereas edoxaban tended to be associated with a lower GI bleeding risk compared to rivaroxaban.
In the present well-matched cohort study using nationwide data, the two once-daily dosing NOACs showed 
comparable outcomes. Consistent with the data of RCTs and previous observational data, edoxaban tended to 
be associated with a lower GI bleeding risk compared to rivaroxaban, but the difference was not statistically 
Figure 3. Cumulative incidence of six clinical outcomes in rivaroxaban and edoxaban groups. Abbreviation: 
GI, gastrointestinal; ICH, intracranial hemorrhage.
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Figure 4. Sensitivity analyses restricting the follow-up duration to 6-month and from same period. 
Abbreviation: CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; ICH, intracranial hemorrhage.
Figure 5. Hazard ratios for ischemic stroke, intracranial hemorrhage, all-cause death, and composite outcome 
according to subgroups in rivaroxaban and edoxaban groups. Abbreviation: CI, confidence interval; CrCl, 
creatinine clearance; HR, hazard ratio; ICH, intracranial hemorrhage.
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significant. All six outcomes were generally consistent across all subgroups and no significant interaction was 
found between treatment and specific subgroups, but with some exceptions. Edoxaban was associated with a 
lower risk of hospitalization for GI bleeding in female patients and in patients with CrCl >50 mL/min. Although 
the results of subgroup analyses should be carefully interpreted, some differential effects detected in patients 
with different clinical profile might be useful for physicians to be able to fit the treatment to their patient’s clinical 
profile.
Reduced dose NOACs are frequently prescribed in the Asian population regardless of label adherence of dos-
ing8,9,11. In this study, CrCl and body weight were available in only 80% of patients; thus, label adherence of NOAC 
dosing could not be fully evaluated. Among patients with available CrCl value and body weight information, 
93% on rivaroxaban 15/10 mg and 44% on edoxaban 30 mg received inappropriate dose reduction. In previous 
studies, prescription of inappropriately reduced dose NOACs (off-label NOAC underdosing) was associated with 
an increased risk of stroke without a benefit in safety26,27. However, the clinical implications of off-label NOACs 
underdosing remains controversial. Asian patients have relatively lower body weight than non-Asian patients and 
are more prone to bleeding, including ICH with warfarin5,28. Hence, some Asian countries have adopted different 
dosing regimens for rivaroxaban using 15 mg as a standard dose29. Although edoxaban and rivaroxaban showed 
similar trends of HRs in both standard and reduced dose regimens in this study, these data should be cautiously 
interpreted because reduced dose groups included a substantial portion of patients with off-label underdosing of 
NOACs.
study limitations. Several limitations of this study should be acknowledged. First, despite using several 
variables and applying advanced statistical methods like propensity score matching to reduce the effect of con-
founding, we cannot completely eliminate bias from residual confounding by physicians’ treatment decisions 
and unmeasured factors, which is a general limitation of observational studies. Thus, we could not measure the 
variables that were not included within the claims database. Second, we used widely used definitions of covariates 
and clinical outcomes which were also validated in our previous studies9,11,30–32. However, there is inherent limita-
tion based on claim data. Third, patients with prior ischemic stroke, ICH, or GI bleeding were excluded from this 
study. Incident episodes of those particular events were not validated to allow differentiation with previous events 
in those who had a prior history of ischemic stroke, ICH, or GI bleeding events; therefore, the results of this study 
could not be extrapolated to those with history of ischemic stroke, ICH, or GI bleeding. Compared to pivotal 
RCTs, our study population had lower mean CHADS2 score (3.5 in ROCKET-AF13, 2.8 in ENGAGE-AF14 and 1.7 
in both rivaroxaban and edoxaban groups in this study). Further study would be needed for multi-morbid and 
high-risk patients. Fourth, given the more recent introduction of edoxaban in the market, the follow-up period 
for edoxaban was shorter than rivaroxaban. Although we demonstrated the consistent results after adjusting for 
the differences in follow-up duration and period between two groups, overall short follow-up duration in both 
treatment groups could be still a limitation. It is unclear whether more significant divergence in clinical outcomes 
between two treatment groups after long-term follow-up. Fifth, the cause of death was not available in this data-
set, thus we could not provide the HR of cardiovascular and non-cardiovascular death. However, consistent with 
previous studies based on observational database, we have only reported the results of all-cause death as one of 
Figure 6. Hazard ratios for hospitalization for gastrointestinal bleeding and hospitalization for major bleeding 
according to subgroups in rivaroxaban and edoxaban groups. Abbreviation: CI, confidence interval; CrCl, 
creatinine clearance; GI, gastrointestinal; HR, hazard ratio.
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relevant hard end points8,9,11,21. Sixth, although there are recently published and on-going trials about NOAC use 
in patients with AF and special clinical situations such as percutaneous coronary intervention33,34 or AF catheter 
ablation35,36, the numbers of patients who underwent procedures in the present study were too small (less than 
2%), so further analyses would not be feasible. Finally, the actual drug adherence could not be evaluated owing to 
the inherent limitation of claims data.
Despite these limitations, overall, rivaroxaban and edoxaban showed comparable results in effectiveness and 
safety from this study. There has been lack of information about the effectiveness and safety of edoxaban, lastly 
introduced NOAC, compared to rivaroxaban, especially in “real-world setting in Asians”. Based on our study 
results, edoxaban could be a good treatment option for patients who want lower pill burden, as well as being 
preferred in patients concerned about GI bleeding events when considering two possible options of once-daily 
dosing NOACs. Once-daily regimens could be more convenient than twice-daily regimens; therefore, higher 
medication adherence would be expected37. Theoretically, the clinical impact of a single dose missed might be 
greater in once-daily dosing than twice-daily dosing38. In clinical practice, therefore, once-daily dosing NOACs 
may require more vigilance for missed doses or non-adherence, and various efforts to improve drug adherence 
should be implemented10,39.
Conclusions
To our knowledge, this is the first head-to-head comparison of the effectiveness and safety between the two 
once-daily NOAC regimens (rivaroxaban, edoxaban) in a nationwide Asian cohort with non-valvular AF. In both 
standard and reduced dose matching cohorts, edoxaban and rivaroxaban were associated with similar outcomes 
for ischemic stroke, ICH, hospitalization for GI bleeding and major bleeding, all-cause death, and the composite 
outcome.
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